This review provides an introduction to the principle underlying production of monoclonal antibodies and highlights current areas where these antibodies have been successfully introduced into practice of pathology and laboratory medicine.
Principles of monoclonal antibody production:
The principle involved in production of monoclonal antibodies is isolation and immortalization of antibody-producing B-lymphocytes or plasma cells from an immunized animal. In order to achieve this, it is necessary to fuse these lymphocytes with malignant B-lymphocytes from myeloma or plasmacytoma. Director, *Assistant and filled with a slightly electron dense amorphous material and a large Golgi complex. Fig. 1B shows an electron micrograph of mouse myeloma cells from line P3-X63-Ag8.653 which is most widely used for fusion with antibody-producing B-lymphocytes. The cells have bizarre-shaped nuclei located slightly eccentrically with dense chromatin masses and swollen mitochondria with a loss of cristae. The endoplasmic reticulum is well-developed and shows flattened sacs containing numerous virus-like particles which are exclusively of a "doughnut" form (inset). It should be noted that normal B-lymphocytes can not be grown up and maintained in vitro, while malignant myeloma cells have the ability to grow indefinitely and form colony either in vitro or when injected into suitable animals. Therefore, it is natural that the daughter cells resulting from the fusion should inherit some characteristics from both parents. These include immortality from the malignant myeloma cells and an antibody producing ability from the B- The antibodies produced in this way are screened to identify the desired clone using a variety of assays including radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Monoclonal antibodies promise significant advances in many areas of biotechnology which are continually expanding. Several areas in which these antibodies have found potential applications are considered here.
Perhaps the most exciting potential use of monoclonal antibody technology has been in the field of cancer diagnosis, prognosis and therapy. Malignant tumors are characterized by a rapid growth, invasive potentiality, and a spread via the blood stream or lymphatics to create distant tumor deposits known as metastases. Presence or absence of these metastases usually determines (223)5 whether the patients will die or live. Such metastases also provide a source for further spread of the tumor. Although it may be possible to eradicate the primary tumor by means of surgery or radiotherapy, eradication of metastases generally has been impossible and this in turn accounts for treatment failure which ultimately kills the patient.
With the advent of monoclonal antibodies more specific, pure, and homogenous reagents will be available to assess cancerous patients. These antibodies may be used for more reliable detection of specific circulating tumor markers, thus improving the accuracy of diagnosis, treatment decision and monitoring the patient . They may be also coupled with radio-active agents and used to localize the tumors.
In cancer therapy, monoclonal antibodies may be used either alone as for immunotherapy or coupled with the cytotoxic or radio-active agents to enhance the uptake of these agents by the tumors. Cancerous patients receiving aggressive chemotherapy often develop severe bone marrow suppression requiring marrow transplantation. Monoclonal antibodies may be used for removal of T-lymphocytes from donor bone marrow before transplantation to avoid the graft-versus-host (GVH) disease. lesion, the detection of origin of tumors, the demonstration of very small foci of tumors, the discrimination between similar tumors, the determination of the site of marker substance production, and the determination of the most useful marker substance for monitoring the patient. Several applications of monoclonal antibodies in cancer diseases are summerized in Table 2 . Monoclonal antibody to prostate-specific antigen assists in the detection of prostatic origin of a tumor and also demonstration of micrometastases from prostatic carcinoma in the lymph nodes. Fig. 5B shows localization of prostate-specific antigen in an established prostatic cell line (DU-145) by indirect immunoflourescence method. Fig. 5C demonstrates micrometastases from prostatic carcinoma in the lymph node using PAP technique for prostate-specific antigen.
Monoclonal antibody to carcinoembryonic antigen (CEA) is useful in determining the course of a cancer disease during follow up. Localization of CEA in tumors has been correlated with poor differentiation and metastasis. The consistent quality and homogenous nature of monoclonal antibodies make them ideal probes for immuno-electron microscopy with the resolution of many problems not possible with polyclonal sera. Fig. 8B performed in England is done using commercially available monoclonal anti-A and anti-B blood group reagents. Organ transplantation of the kidney, liver, bone marrow and the heart is now increasing and accurate typing of the histocompatibility leukocyte antigens (HLA) present in the cells plays an important role . Application of monoclonal antibodies especially those of human origin produced against HLA antigens would certainly improve the accuracy of such determination.
The advantages and disadvantages of monoclonal antibodies for tissue diagnosis are summerized in Table 3 . Undoubtedly, there are many areas of science in which monoclonal antibodies may hold promise. Hopefully, the generation of human monoclonal antibodies is now feasible, which certainly obviates several disadvantages of animal antibodies .
